The estimated Net Worth of Clay Hatteras Venture Advis... is at least $63.4 million dollars as of 30 May 2018. Clay Advis owns over 800,000 units of G1 Therapeutics Inc stock worth over $23,084,879 and over the last 7 years Clay sold GTHX stock worth over $40,316,625.
Clay has made over 2 trades of the G1 Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Clay sold 800,000 units of GTHX stock worth $38,400,000 on 30 May 2018.
The largest trade Clay's ever made was selling 800,000 units of G1 Therapeutics Inc stock on 30 May 2018 worth over $38,400,000. On average, Clay trades about 279,167 units every 3 days since 2017. As of 30 May 2018 Clay still owns at least 3,237,711 units of G1 Therapeutics Inc stock.
You can see the complete history of Clay Advis stock trades at the bottom of the page.
Clay's mailing address filed with the SEC is 79 T W Alexander Drive #4501 Ste 100, Research Triangle Park, NC 27709, United States.
Over the last 7 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman et Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
G1 Therapeutics Inc executives and other stock owners filed with the SEC include: